197 related articles for article (PubMed ID: 27920531)
1. In vitro evaluation of folic acid-conjugated redox-responsive mesoporous silica nanoparticles for the delivery of cisplatin.
Alvarez-Berríos MP; Vivero-Escoto JL
Int J Nanomedicine; 2016; 11():6251-6265. PubMed ID: 27920531
[TBL] [Abstract][Full Text] [Related]
2. Targeted anticancer prodrug with mesoporous silica nanoparticles as vehicles.
Fan J; Fang G; Wang X; Zeng F; Xiang Y; Wu S
Nanotechnology; 2011 Nov; 22(45):455102. PubMed ID: 22019849
[TBL] [Abstract][Full Text] [Related]
3. Cancer-targeted and intracellular delivery of Bcl-2-converting peptide with functional macroporous silica nanoparticles for biosafe treatment.
Wu Y; Ge P; Xu W; Li M; Kang Q; Zhang X; Xie J
Mater Sci Eng C Mater Biol Appl; 2020 Mar; 108():110386. PubMed ID: 31923940
[TBL] [Abstract][Full Text] [Related]
4. PEG-templated mesoporous silica nanoparticles exclusively target cancer cells.
Morelli C; Maris P; Sisci D; Perrotta E; Brunelli E; Perrotta I; Panno ML; Tagarelli A; Versace C; Casula MF; Testa F; Andò S; Nagy JB; Pasqua L
Nanoscale; 2011 Aug; 3(8):3198-207. PubMed ID: 21725561
[TBL] [Abstract][Full Text] [Related]
5. Ultrasound-Triggered Destruction of Folate-Functionalized Mesoporous Silica Nanoparticle-Loaded Microbubble for Targeted Tumor Therapy.
Lv Y; Cao Y; Li P; Liu J; Chen H; Hu W; Zhang L
Adv Healthc Mater; 2017 Sep; 6(18):. PubMed ID: 28671341
[TBL] [Abstract][Full Text] [Related]
6. Folic acid-hydrophilic polymer coated mesoporous silica nanoparticles target doxorubicin delivery.
Al-Nadaf AH; Dahabiyeh LA; Jawarneh S; Bardaweel S; Mahmoud NN
Pharm Dev Technol; 2021 Jun; 26(5):582-591. PubMed ID: 33729906
[TBL] [Abstract][Full Text] [Related]
7. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.
Ma X; Zhao Y; Ng KW; Zhao Y
Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533
[TBL] [Abstract][Full Text] [Related]
8. Hybrid inorganic (nonporous silica)/organic (alginate) core-shell platform for targeting a cisplatin-based Pt(IV) anticancer prodrug.
Ravera M; Gabano E; Bonzani D; Zanellato I; Arrais A; Cantamessa S; Biggiogera M; Osella D
J Inorg Biochem; 2018 Dec; 189():185-191. PubMed ID: 30312905
[TBL] [Abstract][Full Text] [Related]
9. Controlled synthesis and size effects of multifunctional mesoporous silica nanosystem for precise cancer therapy.
Ma B; He L; You Y; Mo J; Chen T
Drug Deliv; 2018 Nov; 25(1):293-306. PubMed ID: 29334793
[TBL] [Abstract][Full Text] [Related]
10. Multifunctional mesoporous silica nanoparticles modified with tumor-shedable hyaluronic acid as carriers for doxorubicin.
Zhang J; Sun Y; Tian B; Li K; Wang L; Liang Y; Han J
Colloids Surf B Biointerfaces; 2016 Aug; 144():293-302. PubMed ID: 27107383
[TBL] [Abstract][Full Text] [Related]
11. The intracellular controlled release from bioresponsive mesoporous silica with folate as both targeting and capping agent.
Guo R; Li LL; Zhao WH; Chen YX; Wang XZ; Fang CJ; Feng W; Zhang TL; Ma X; Lu M; Peng SQ; Yan CH
Nanoscale; 2012 Jun; 4(11):3577-83. PubMed ID: 22543578
[TBL] [Abstract][Full Text] [Related]
12. Delivery of Gemcitabine Prodrugs Employing Mesoporous Silica Nanoparticles.
Malfanti A; Miletto I; Bottinelli E; Zonari D; Blandino G; Berlier G; Arpicco S
Molecules; 2016 Apr; 21(4):522. PubMed ID: 27110750
[TBL] [Abstract][Full Text] [Related]
13. Human Serum Albumin Conjugated Nanoparticles for pH and Redox-Responsive Delivery of a Prodrug of Cisplatin.
Shi H; Cheng Q; Yuan S; Ding X; Liu Y
Chemistry; 2015 Nov; 21(46):16547-54. PubMed ID: 26405808
[TBL] [Abstract][Full Text] [Related]
14. Tumour-Targeted and Redox-Responsive Mesoporous Silica Nanoparticles for Controlled Release of Doxorubicin and an siRNA Against Metastatic Breast Cancer.
Zhuang J; Chen S; Hu Y; Yang F; Huo Q; Xie N
Int J Nanomedicine; 2021; 16():1961-1976. PubMed ID: 33727809
[TBL] [Abstract][Full Text] [Related]
15. Controlled release of silyl ether camptothecin from thiol-ene click chemistry-functionalized mesoporous silica nanoparticles.
Yan Y; Fu J; Wang T; Lu X
Acta Biomater; 2017 Mar; 51():471-478. PubMed ID: 28131940
[TBL] [Abstract][Full Text] [Related]
16. An optimized mesoporous silica nanosphere-based carrier system with chemically removable Au nanoparticle caps for redox-stimulated and targeted drug delivery.
Zhang L; Wei F; Al-Ammari A; Sun D
Nanotechnology; 2020 Nov; 31(47):475102. PubMed ID: 32413886
[TBL] [Abstract][Full Text] [Related]
17. Targeted delivery of quercetin loaded mesoporous silica nanoparticles to the breast cancer cells.
Sarkar A; Ghosh S; Chowdhury S; Pandey B; Sil PC
Biochim Biophys Acta; 2016 Oct; 1860(10):2065-75. PubMed ID: 27392941
[TBL] [Abstract][Full Text] [Related]
18. A dual-functional HER2 aptamer-conjugated, pH-activated mesoporous silica nanocarrier-based drug delivery system provides in vitro synergistic cytotoxicity in HER2-positive breast cancer cells.
Shen Y; Li M; Liu T; Liu J; Xie Y; Zhang J; Xu S; Liu H
Int J Nanomedicine; 2019; 14():4029-4044. PubMed ID: 31213813
[No Abstract] [Full Text] [Related]
19. Redox-responsive nanocarriers for drug and gene co-delivery based on chitosan derivatives modified mesoporous silica nanoparticles.
Lin JT; Liu ZK; Zhu QL; Rong XH; Liang CL; Wang J; Ma D; Sun J; Wang GH
Colloids Surf B Biointerfaces; 2017 Jul; 155():41-50. PubMed ID: 28407530
[TBL] [Abstract][Full Text] [Related]
20. Self-controlled release of Oxaliplatin prodrug from d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) functionalized mesoporous silica nanoparticles for cancer therapy.
Liang C; Wang H; Zhang M; Cheng W; Li Z; Nie J; Liu G; Lian D; Xie Z; Huang L; Zeng X
J Colloid Interface Sci; 2018 Sep; 525():1-10. PubMed ID: 29679795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
